The National Institutes of Health will begin testing an experimental Ebola vaccine in people as early as September. In March, a group at UTMB, led by Thomas Geisbert, a professor of microbiology and immunology, was awarded a five year, $26 million grant to work with three promising Ebola therapies. Geisbert is best known as the man who discovered an airborne strain of Ebola that infects only monkeys. The grant covers three treatments that are thought to be the most promising — i.e., they have shown substantial ability to protect animals against Ebola in a laboratory setting, Geisbert said.